Related by context. All words. (Click for frequent words.) 71 clinically meaningful 62 pharmacodynamic PD 61 clinically meaningful improvement 61 pharmacodynamic 60 clinically meaningful differences 60 RE LY trial 60 viral kinetics 60 DBMD 59 ataluren 59 teriflunomide 59 dose proportionality 59 vidofludimus 59 atherosclerosis regression 59 clinically meaningful improvements 59 antiangiogenic agents 59 therapeutically relevant 58 efficacy tolerability 58 favorable pharmacokinetic profile 58 pharmacologic 58 Hedgehog inhibitor 58 CINQUIL 58 p# inhibitor 58 velafermin 58 clinically 58 demonstrated clinically meaningful 58 physiologic 58 analgesic efficacy 58 corrected QT interval 57 periprocedural MI 57 epoetin alpha 57 tolerability 57 IOP lowering 57 molecular biomarkers 57 prognostic markers 57 stratifying patients 57 preclinically 57 haematologic 57 pharmacological 57 immunomodulation 57 multicenter trials 57 lipid parameters 57 radioimmunotherapy RIT 57 histologies 57 prognostic indicators 57 physiologically relevant 57 EQ 5D 57 plasma pharmacokinetics 57 platelet reactivity 57 pathophysiologic 57 systemically administered 57 Hsp# inhibition 57 adrenal suppression 57 oncologic outcomes 57 Aggrastat ® tirofiban hydrochloride 57 fondaparinux 57 fosbretabulin 57 ADHF 57 S/GSK# 57 prespecified 57 masitinib 57 pharmacokinetic PK 56 preclinical efficacy 56 etiologic 56 pharmacodynamic profile 56 FDG PET imaging 56 hyperphenylalaninemia HPA due 56 LT NS# 56 intracoronary 56 biochemical abnormalities 56 Azedra 56 tipranavir 56 clinically meaningful reductions 56 antitumour activity 56 predictive biomarker 56 thromboembolic 56 antipsychotic efficacy 56 bronchodilation 56 thromboembolic events 56 caspofungin 56 dosing frequency 56 antitumor activity 56 Subgroup analyzes 56 cardioprotective effects 56 antiarrhythmic drug 56 definite stent thrombosis 56 pharmacoeconomic 56 neurocognitive function 56 pulmonary toxicity 56 echocardiographic 56 biologic plausibility 56 breast cancer subtypes 56 radezolid 56 therapeutic regimens 56 achieved statistical significance 56 secondary efficacy endpoints 56 GFT# 56 tumor histology 56 noninferiority 56 clinical pharmacology studies 56 biomarker assay 56 pharmacokinetic equivalence 56 CYT# potent vascular disrupting 56 physiologic mechanisms 56 antitumor effect 56 dose limiting toxicities 56 GMX# 56 bronchodilatory 56 ADAGIO study 56 paclitaxel eluting stents 55 Trofex 55 genotypic 55 AGHD 55 Virulizin ® 55 antiangiogenic therapy 55 scintigraphic 55 pharmacodynamic parameters 55 pharmacologic intervention 55 ON #.Na 55 pharmacodynamic effects 55 Solid Tumors 55 LHRH antagonists 55 GAMMAGARD 55 cardiac repolarization 55 Multimeric 55 #ME# 55 tolerability profile 55 concomitant medications 55 NP2 Enkephalin 55 decitabine 55 T1DM 55 Ophena TM 55 serum biomarkers 55 intravascular hemolysis 55 β blockers 55 clevidipine 55 Symadex 55 HuMax EGFr 55 pharmacodynamic markers 55 alicaforsen enema 55 biomarker 55 intracerebral haemorrhage 55 primary endpoint 55 lenalidomide dexamethasone 55 sJIA 55 clinically meaningful efficacy 55 sUA 55 Secondary endpoints include 55 statistically significant 55 intravenous immunoglobulin IVIg 55 clinical 55 pharmacokinetic 55 neurosensory 55 vivo potency 55 ATACAND 55 pressor response 55 Natalizumab 55 serum concentrations 55 retinal thickness 55 antithrombotic therapy 55 Neuropsychiatric Inventory NPI 55 NNRTI resistance 55 rFVIIa 55 florbetaben 55 rEEG 55 Pharmacokinetic 55 prospective multicenter study 55 isatoribine 55 postoperative AF 55 pain palliation 55 ganetespib 55 prostate cancer CaP 55 symptomatic VTE 55 parkinsonian symptoms 55 adrenomedullin 55 pharmacokinetics PK 55 riociguat 55 myeloproliferative disorders 55 NLX P# 55 histopathological 55 statistically significant p = 55 STRIDE PD 55 TNF alpha antagonist 55 maximally tolerated dose 55 radiolabeled TM# 55 alteplase 55 adalimumab 55 RECIST Response Evaluation Criteria 55 apoB 55 CTAP# Capsules 55 histologic 55 Gag polymorphisms 55 null responder 55 liver histology 55 therapeutic armamentarium 55 desvenlafaxine succinate 55 biodistribution 55 WOMAC pain 55 skin sterol 55 FFR measurements 55 diagnostic prognostic 55 immunologic 54 lesional 54 dyslipidaemia 54 relapsed SCLC 54 macrovascular events 54 delafloxacin 54 coagulation abnormalities 54 PASI scores 54 IFN beta 54 carotid IMT 54 investigational therapies 54 clinicopathological 54 dosage regimens 54 headache nasopharyngitis 54 pomalidomide 54 secondary endpoints 54 efficacy 54 kidney urologic 54 metastatic neuroendocrine tumors 54 electrophysiologic 54 nonpharmacologic 54 xenograft models 54 chemosensitivity 54 FTIs 54 mTOR inhibition 54 morphologic 54 aetiology 54 Campath alemtuzumab 54 hour bronchodilation 54 topical NSAIDs 54 complete cytogenetic response 54 erythropoietic 54 EBUS FNA 54 oral diclofenac 54 NATRECOR ® 54 SSc 54 MDS MPD 54 HER2 expression 54 comorbid conditions 54 pharmacogenetic testing 54 Valdoxan 54 hematological parameters 54 knee osteoarthritis OA 54 platelet inhibition 54 secondary endpoint 54 RAPAFLO R 54 micafungin 54 biomarkers 54 nicardipine 54 CIMZIA TM certolizumab pegol 54 Randomized clinical trials 54 prespecified secondary 54 stratify patients 54 PXD# 54 extracranial 54 elevated creatinine 54 HRQL 54 linear pharmacokinetics 54 Multivariate logistic regression 54 neuroprotection 54 Secondary endpoints included 54 HES CEL 54 hMG 54 #F FDG PET 54 rt PA 54 AST ALT 54 CTEPH 54 convenient dosing regimen 54 JAK inhibitors 54 antiplatelet therapies 54 serum lipid 54 pathophysiological 54 immunohistochemical 54 p# activation 54 resynchronization therapy 54 viral kinetic 54 antidepressant efficacy 54 GnRH agonists 54 Doxil ® 54 Src inhibitors 54 complete remissions 54 seropositive patients 54 CRLX# 54 perfusion CT 54 MMP inhibitors 54 reproducible 54 ibandronate 54 platelet function 54 pericardial effusion 54 FFR guided treatment 54 Elocalcitol 54 bronchial hyperresponsiveness 54 TNF antagonist 54 varespladib 54 interferon beta therapy 54 intact parathyroid hormone 54 Psoriasis Area 54 Non inferiority 54 oral FTY# 54 multiplex assay 54 unstable angina UA 54 relapsing multiple sclerosis 54 pharmacokinetic interactions 54 p# biomarker 54 hematologic adverse 54 Pharmacokinetics PK 54 VAPRISOL 54 NIHSS 54 histopathologic 54 pharmacokinetic PK profile 54 tumor hypoxia 54 novel VDA molecule 54 liposomal amphotericin B 54 cerebral oximetry 54 T1a 54 airway hyperresponsiveness 54 atherothrombotic disease 54 immunostimulatory effects 54 visceral metastases 54 pertuzumab 54 blood Phe 54 Vojo Vukovic MD Ph.D. 54 mg dose 54 antithrombotic therapies 54 HORIZONS AMI trial 54 serum phosphate 54 ischemic cardiovascular 54 SERCA2a 54 olanzapine LAI 54 Zevalin consolidation 54 multimodality imaging 54 ADCS CGIC 54 everolimus eluting stents 54 hypercalcemia 54 antiplatelet 54 cardiovascular calcification 54 HIV HCV coinfected 54 hypoxic tumors 54 favorable tolerability 54 insulin degludec 54 pharmacological interventions 54 APOPTONE 54 certolizumab 54 thrombotic complications 54 FDG-PET/CT 54 nephrotoxicity 54 eniluracil 54 pCR 54 disease progression 53 antithrombotic 53 IMPROVE HF 53 C1 INH 53 pharmacodynamics 53 airway responsiveness 53 antitumor efficacy 53 myeloperoxidase 53 timepoint 53 6MWD 53 vitro cytotoxicity 53 pharmacodynamic endpoints 53 DCCR 53 endothelial activation 53 mTOR inhibitors 53 genotypic resistance 53 carcinoids 53 relapsed ALL 53 UGT#A# * 53 etanercept 53 apremilast 53 subgroup analyzes 53 evaluable 53 Corus CAD 53 statistically significant improvement 53 gene rearrangements 53 oral anticoagulation 53 obatoclax 53 monoclonal antibody therapies 53 inflammatory biomarkers 53 CCyR 53 androgen deprivation 53 pharmacodynamic properties 53 catheter occlusion 53 murine models 53 blood Phe levels 53 SYNTAX trial 53 NNT = 53 avosentan 53 clinical endpoints 53 HIF PH inhibitors 53 SABCS 53 REMINYL ® 53 intracranial hemorrhage ICH 53 PKCi 53 miglustat 53 IL 1ß 53 cardiac perfusion 53 MarginProbe 53 antiproliferative effects 53 methylation markers 53 mGluR5 antagonist 53 lethal arrhythmias 53 postoperative radiotherapy 53 Triapine R 53 EGFR mutation status 53 placebo controlled clinical 53 CBLC# 53 EDEMA3 trial 53 demonstrated antitumor activity 53 HDL Selective Delipidation 53 CYPHER R Sirolimus eluting 53 allogeneic HSCT 53 glatiramer acetate 53 PEGPH# 53 hoFH patients 53 TOLAMBA 53 ALA PDT 53 tissue oxygenation 53 endothelin receptor antagonists 53 BoNTA 53 symptom severity 53 ticagrelor 53 XP #L 53 hemoglobin A1c HbA1c 53 TKM ApoB 53 targeting CD# 53 clinically insignificant 53 mutated K ras 53 MET amplification 53 efficacy endpoints 53 tumor specific antigen 53 glycated hemoglobin levels 53 aldosterone antagonists 53 pharmacologic treatments 53 treprostinil 53 IGFBP 3 53 CIPN 53 limiting toxicity 53 response CCyR 53 mucosal healing 53 APOE genotype 53 neurophysiological 53 cediranib 53 tipranavir r 53 ESBA# 53 Sudhir Agrawal D.Phil 53 RezularTM 53 teratogenic 53 PRADAXA 53 AZILECT ® 53 PSADT 53 BNC# 53 Thrombolysis 53 statistical significance 53 RNAi therapeutic targeting PCSK9 53 selective agonists 53 anti angiogenic agents 53 HAQ DI 53 diagnostic biomarker 53 Ophena 53 surrogate markers 53 metaanalysis 53 intermittent dosing 53 GLYX 53 Clinically 53 optimal dosing 53 lipid lowering drugs 53 secretory phospholipase A2 sPLA2 53 tigecycline 53 inflammatory lesions 53 crizotinib PF # 53 splice variants 53 anti leukemic 53 calcitonin 53 busulfan 53 CIMZIA TM 53 CDK inhibitor 53 nonrandomized 53 CIMZIA ™ 53 recurrent DVT 53 transcranial Doppler 53 serum urate 53 pramlintide metreleptin combination 53 inhaled nitric oxide 53 ELACYT 53 ADAS Cog 53 angiographically 53 bexarotene 53 dopaminergic therapy 53 TroVax ® 53 infarct size 53 uricase 53 cannabinor 53 Crohn Disease Activity 53 Bezielle 53 K ras mutations 53 immunoregulatory 53 TRIOLEX 53 IgG antibody 53 serum antibody 53 mechanistic insights 53 Meta analyzes 53 HIV RNA 53 thromboembolism 53 rheumatologic 53 hypoglycemic events 53 laboratory abnormalities 53 Secondary endpoints 53 pituitary adenomas 53 pharmacokinetic characteristics 53 sonographic diagnosis 53 Vaxfectin R 53 PRTX 53 endometrial hyperplasia 53 radiographic outcomes 53 myeloproliferative diseases 53 intravenous immunoglobulin IVIG 53 molecular remissions 53 non selective NSAIDs 53 trastuzumab Herceptin ® 53 circulating EPCs 53 pathologic 53 genomic alterations 53 lung fibrosis 53 ketorolac 53 ACUITY trial 53 invasive candidiasis 53 prostanoid 53 HER2 overexpression 53 NIH CPSI 53 ENMD # 53 A3 adenosine receptor 53 anticoagulation 53 imatinib therapy 53 mg kg dose 53 postmenopausal osteoporotic women 53 γ secretase 53 vWF 53 thromboprophylaxis 53 Pharmacokinetic studies 53 vinca alkaloid 53 TRV# [001] 53 torezolid phosphate 53 F FDG PET 53 #beta HSD1 53 glaucomatous 53 tocilizumab 53 orally inhaled migraine 53 heparanase 53 diagnostic modality 53 CR# vcMMAE 53 hepatocellular 53 fluvastatin 53 virologic 53 RoACTEMRA 53 TDF FTC 53 microdose 53 secondary efficacy endpoint 53 LB# [003] 53 serum BDNF 53 MERLIN TIMI 53 SGRQ 53 vivo 53 mycophenolate mofetil 53 cardiac troponin 53 statistically significant reduction 53 thrombogenic 53 anti fibrotic 53 INCB# [001] 53 virologic responses 53 COPD exacerbations 53 kinase inhibition 53 myocardial ischemia 53 CA9 SCAN 53 renoprotective 53 VP# [004] 53 talactoferrin 53 BAL# [002] 53 SCIg 53 vascular disrupting agents 53 FDG PET 53 OAB symptoms 53 intracranial stenosis 53 neoplastic 53 ZFP TF 53 direct thrombin inhibitors 53 basal bolus regimen 53 B7 H3 53 nadolol 53 tezampanel 53 plus octreotide LAR 53 KRAS variant 53 eculizumab therapy 53 Tectin TM 53 HMG CoA reductase inhibitors 53 PEGylated interferon beta 1a 53 immunomodulatory 53 molecularly targeted therapies 53 antiarrhythmic 53 prolonged QT interval 53 noninferior 53 NSCLC tumors 53 glomerular filtration 53 antiphospholipid antibodies 53 KL4 surfactant 53 hyperbilirubinemia 53 verteporfin 53 VEGF inhibitors 53 HbF 53 chronic LBP 53 DLTs 53 M6G 53 congenital anomalies 53 artery stenosis 53 KRN# 53 clobazam 53 timepoints 53 KRAS oncogene 53 monotherapy 53 pyridostigmine 53 morphometric vertebral fractures 53 paricalcitol 53 hemodynamic 53 safety tolerability pharmacokinetic 52 Primary endpoints 52 BEXXAR Therapeutic Regimen 52 MAGE A3 ASCI 52 microvascular complications 52 CANCIDAS 52 pharmacological approaches 52 ZFP Therapeutic 52 XmAb# 52 sipuleucel T 52 CCX# 52 tumor regression 52 pharmacokinetic parameters 52 PCWP 52 KRAS status 52 microRNA profiling 52 QT QTc 52 antiviral efficacy 52 omecamtiv mecarbil 52 non pharmacological interventions 52 induced sputum 52 neuropathological 52 rheumatoid arthritis osteoarthritis ankylosing 52 NGAL 52 AT1R 52 sirolimus eluting stents 52 antithrombotics 52 microarray gene expression 52 mammographic density 52 seliciclib 52 tolvaptan 52 rtPA 52 Hemospan R 52 DAVANAT 52 CEACAM1 52 HSCT 52 anti angiogenic drugs 52 DAPT 52 JAK2 inhibitor 52 fulvestrant 52 recurrent glioma 52 proliferative diabetic retinopathy 52 Tasigna prolongs 52 MP4OX 52 pamidronate 52 sustained virologic response 52 5q deletion 52 selenium supplementation 52 atherothrombosis 52 hyperacute 52 presymptomatic 52 prophylactic therapy 52 neurotrophic 52 cisplatin resistant 52 EpCAM expression 52 perfusion imaging 52 neurologic progression 52 statistical significance p 52 IPL# 52 EGFR blockers 52 plasma lipid 52 ascending dose 52 oncological outcomes 52 tumorigenicity 52 metaglidasen 52 highly immunogenic 52 pan HDAC inhibitor 52 OHR/AVR# 52 ConclusionThis 52 Octreolin 52 rBChE 52 VKORC1 52 RRMS patients 52 enoximone 52 tolerability profiles 52 HbA 1c levels 52 fibrotic disease 52 neurophysiologic 52 pharmacologic approaches 52 TMS Therapy 52 ZOLINZA 52 QTc 52 relapsed MM 52 MEK inhibitors 52 constipation OIC 52 OMNARIS HFA 52 serologically active patients 52 AZX# 52 pharmacokinetic PK study 52 INCB# [003] 52 paliperidone ER 52 pretest probability 52 metastatic gastric 52 NPM1 52 Pharmacodynamic 52 Teriflunomide 52 endometrial thickness 52 epigenomic 52 intraobserver 52 Secondary efficacy endpoints 52 MCyR 52 ACTEMRA TM 52 ProSavin 52 comorbidities 52 DACH platinum 52 belimumab 52 natriuretic peptides 52 receptor inhibitor 52 posaconazole 52 virologic response 52 safinamide 52 genetic polymorphisms 52 thrombolytic therapy 52 Galectin 3 52 cytogenic 52 relapsed MCL 52 GRNCM1 52 GRN# 52 UPDRS scores 52 antiangiogenic agent 52 RE LY ® 52 WT1 52 adrenalectomy 52 nonclinical studies 52 intranasal delivery 52 aPTT 52 atacicept 52 Haptoglobin 52 antiemetics 52 tanespimycin 52 experimentally induced 52 cangrelor 52 ALGRX 52 Tarceva TM 52 underlying pathophysiology 52 LV dysfunction 52 virological response 52 peptide antigens 52 HGS ETR2 52 haemodynamic 52 ischemic cardiomyopathy 52 insulin glargine 52 GOUT 52 composite endpoint 52 elagolix 52 reinfarction 52 lactate dehydrogenase LDH 52 Isolagen Therapy 52 statistically significant p 52 QTinno 52 epigenetic markers 52 surrogate endpoint 52 teriparatide 52 lintuzumab 52 LRP5 52 dosing regimens 52 tumor shrinkage 52 LEVADEX 52 ABCB1 52 antioxidant supplementation 52 clefting 52 HyQ 52 ischemic lesions 52 prospectively defined 52 Panzem R NCD 52 immunomodulatory therapy 52 iPTH 52 rALLy trial 52 novel peptide 52 tumor regressions 52 heparin induced thrombocytopenia 52 esophagogastric 52 miRNA expression 52 myopathy rhabdomyolysis 52 ticagrelor Brilinta 52 interferon gamma 1b 52 encapsulates siRNAs 52 Hematologic 52 asthma exacerbations 52 achieve statistical significance 52 chlamydial 52 prognostically 52 cobiprostone 52 YONDELIS 52 Inhaled AAT 52 Vidaza ® 52 Squalamine 52 ZYBRESTAT 52 eTag assays 52 Vascugel ® 52 methotrexate therapy 52 viral tropism 52 mitochondrial toxicity 52 beta globin gene 52 ARCOXIA 52 thyroid carcinoma 52 statistically significant differences 52 ependymomas 52 DNA methylation markers 52 solifenacin 52 electrocardiographic 52 maturational 52 invasive aspergillosis 52 imetelstat 52 DaTscan 52 dysmenorrhea 52 individualize therapy 52 protease inhibitor PI 52 PSA nadir 52 motor neuron degeneration 52 preclinical pharmacokinetic 52 prostate cancer CRPC 52 hypofractionated 52 MGd 52 thromboembolic disease 52 intestinal mucosal 52 AGILECT R 52 Fc receptor 52 gadolinium enhanced 52 neutralizing antibody 52 carotid stenosis 52 Xelox 52 LHRH agonists 52 Cyclin E 52 HIF PHIs 52 thiopurine 52 atherothrombotic 52 NEVO ™ 52 receptor blocker 52 PRT# 52 Xanafide 52 pharmacotherapeutic 52 bronchoalveolar lavage 52 alemtuzumab MS 52 selective modulator 52 MitraClip device 52 prostatic adenocarcinoma 52 rhGH 52 acute coronary syndromes ACS 52 parathyroidectomy 52 neuronal dysfunction 52 TriRima 52 IRX 2 52 acadesine 52 antiplatelet drugs 52 INT# [002] 52 oral prodrug 52 variceal bleeding 52 pulmonary exacerbations 52 immunological 52 calcineurin inhibitors 52 MAGE A3 52 cytogenetic response 52 metabolomic 52 OncoVEX GM CSF 52 Cardiotoxicity 52 hypercholesterolemia 52 haematopoietic 52 noninvasive imaging 52 EUS FNA 52 antiplatelet agents 52 clinico pathological 52 undetectable HBV DNA 52 antiplatelet medications 52 metabolizer 52 diabetic gastroparesis 52 perioperative complications 52 CoFactor 52 Valortim ® 52 echocardiographic parameters 52 neovascular 52 Vacc 4x 52 phenotypic 52 Generx 52 sustained virological response 52 Catena ® 52 PRECiSE 52 wilate ® 52 Leydig cell 52 MAL PDT 52 therapeutic equivalence 52 lentiviral 52 EchoCRT 52 APOE e4 52 glycemic variability 52 PROCHYMAL 52 angiographic outcomes 52 neurocognitive deficits 52 urate lowering 52 antagomirs 52 Carfilzomib 52 diabetic neuropathic pain 52 Tyrima 52 coronary revascularization 52 imatinib resistance 52 Apoptone 52 LymphoStat B 52 KRAS mutation 52 antihypertensive drugs 52 hematologic 52 Immunohistochemical analysis 52 neurologic complications 52 opioid analgesia 52 BRAF inhibitor 52 immunomodulatory agents 52 therapeutic modality 52 tezampanel NGX# 52 neuroregenerative 52 Perceiva 52 glycosylated hemoglobin HbA1c 52 PEGylated anti 52 anti CD# antibodies 52 troponin T 52 clusterin 52 locoregional recurrence 52 acetabular fractures 52 spirometric 52 ORMD 52 ponatinib 52 oxycodone CR 52 IgG1 antibodies 52 ventricular remodeling 52 prospective multicentre 52 prognostic significance 52 Cleviprex TM clevidipine 52 ancrod 52 PLX cells 52 bFGF 52 pathogenetic mechanisms 52 NEUGENE 52 primary efficacy endpoint 52 BioMAP 52 hepatocellular carcinoma liver 52 idraparinux 52 NAbs 52 methotrexate monotherapy 52 Phase 2a trial 52 randomized clinical trials 52 immunopathology 52 mecamylamine 52 HQK 52 antiangiogenic 52 patients undergoing CABG 52 miRs 52 subclinical hypothyroidism 52 TNF blocker therapy 52 metabonomics 52 Ereska 52 SNP rs# [002] 52 IMiDs ® compound 52 FOLPI 51 prospective longitudinal 51 gastric carcinomas 51 valsartan 51 diagnosing autism 51 aripiprazole Abilify 51 taxane therapy 51 inhaled iloprost 51 NSTE ACS 51 cMET 51 tiotropium 51 quantitative gene expression 51 opioid antagonists 51 ARIKACE ™ 51 ALTROPANE 51 Garcia Manero 51 antifibrotic 51 biochemical marker 51 severe hypersensitivity reactions 51 myocardial revascularization 51 genotoxicity 51 salmeterol HFA MDI 51 heavily pretreated 51 QTc prolongation 51 IIIa inhibitor 51 Visual Analogue Scale VAS 51 ASSERT trial